New research into a chemical produced by a caterpillar fungus that has shown promise as a possible cancer treatment has revealed how it interacts with genes to interrupt cell growth signals.
In a report released yesterday, Jamie Cook from Truist Financial maintained a Buy rating on Caterpillar (CAT – Research Report), with a price target of $454.00. The company’s shares closed ...